Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients

Inclusion Criteria: * Age: Participants must be aged ≥65 years. * Participants must meet the diagnostic criteria for metabolic syndrome according to the 2020 Chinese Type 2 Diabetes Prevention Guidelines, which includes at least three of the following criteria:①Central obesity: Waist circumference ≥90 cm for men, ≥85 cm for women.②Hyperglycemia: Fasting blood glucose ≥6.1 mmol/L or 2-hour post-load glucose ≥7.8 mmol/L, or a confirmed diagnosis of diabetes with ongoing treatment.③Hypertension: Blood pressure ≥130/85 mmHg or a confirmed diagnosis of hypertension with ongoing treatment.④Elevated triglycerides (TG): ⑤Fasting TG ≥1.70 mmol/L. Low HDL cholesterol: Fasting HDL-C \<1.04 mmol/L. * Participants must meet the criteria for "Qi-deficiency and Blood Stasis" syndrome, which includes specific symptoms and signs such as fatigue, shortness of breath, stabbing pain, ecchymosis, and a tongue with purple discoloration or petechiae. * High Cardiovascular Risk: Participants must have at least one of the following: * History of myocardial infarction. * History of stroke or transient ischemic attack. ③History of coronary, carotid, or peripheral artery revascularization. * Coronary, carotid, or lower limb artery stenosis \>50%. ⑤Positive exercise stress test or documented symptomatic coronary heart disease, or unstable angina with ECG changes. * Chronic heart failure (NYHA Class II-III). ⑦Chronic kidney disease (eGFR \<60 ml/min/1.73m²). Exclusion Criteria: * Secondary Abnormalities: Secondary abnormalities in lipids, blood pressure, or blood glucose. * Type 1 Diabetes: Participants with Type 1 diabetes mellitus. * Special Populations: Pregnant or breastfeeding individuals, or those with a history of allergy to the study medication. * Recent Acute Events: Acute coronary or cerebrovascular events within the past 14 days. * Upcoming Revascularization: Planned coronary, carotid, or peripheral artery revascularization. * Severe Heart Failure: Chronic heart failure (NYHA Class IV). * End-Stage Liver Disease: Participants with end-stage liver disease. * Solid Organ Transplantation: History of solid organ transplantation or awaiting solid organ transplantation. * Malignant Tumors: Participants with a history of malignant tumors. * Other Serious Conditions: Any other serious medical conditions that may interfere with the study or pose a risk to the participant.